Rocket Pharmaceuticals, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses), averaging +3.5% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | not reported | $-0.15 | not reported | not reported | |
| Q1 FY26 | $-0.41 | $-0.42 | -2.4% | Miss | |
| Q4 FY25 | $-0.42 | $-0.38 | +9.5% | Beat |
Back to RCKT overview · RCKT holders · RCKT KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.